Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Trial of Niraparib or Niraparib and Bevacizumab Combination in Patients With Recurrent Endometrial Cancer and/or Ovarian Cancer With ARID1A Mutation (OU-SCC-ARID1A)

NCT05523440 is registered in ClinicalTrials.gov with University of Oklahoma as lead sponsor.

NCT NCT05523440
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05523440 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Trial of Niraparib or Niraparib and Bevacizumab Combination in Patients With Recurrent Endometrial Cancer and/or Ovarian Cancer With ARID1A Mutation (OU-SCC-ARID1A)
Lead sponsor
University of Oklahoma
Phase
Phase 2
Overall status
Terminated
Start date
February 15, 2023
Completion date
January 8, 2025
Enrollment
9 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

arid1a gene mutation, recurrent endometrial carcinoma, recurrent ovarian carcinoma